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Abstract 
We are creating a gold-standard corpus of manually annotated full-text biomedical journal articles toward natural-
language-processing applications.  Central to this is our use of entire ontologies of the Open Biomedical Ontologies 
initiative as well as other terminologies as term sources, in contrast to most other such annotation projects, which 
have used small, ad hoc schemas.  In addition to the standard difficulties in such annotation projects, each of the 
terminologies we have used has idiosyncrasies and ambiguities that present further challenges to consistent, high-
quality annotation of these articles.  In this paper we present and discuss the most salient of these with regard to the 
Gene Ontology that we have encountered and addressed in our annotation guidelines and training.  The utility of 
these guidelines can be seen in the high and still-increasing interannotator-agreement statistics that we continually 
monitor. 
Introduction 
Gold-standard annotated biomedical corpora are essential for the training and evaluation of advanced biomedical 
natural-language-processing (NLP) systems, as evidenced by the significantly improved performance statistics of 
such systems trained on relevant corpora1,2.  We have therefore embarked on an ambitious project to create a 
manually annotated corpus of full-text biomedical journal articles as a gold-standard community resource, which we 
are calling the CRAFT (Colorado Richly Annotated Full-Text) Corpus.  In addition to manually annotating full-text 
papers, we are using all terms of select ontologies of the Open Biomedical Ontologies (OBO) initiative3 (as well as 
other terminologies) as the annotating term sources, the first such effort of which we are aware.  One part of this 
effort is annotation of these articles using the entire Gene Ontology (GO), which is comprised of terms representing 
biological processes (BP), molecular functions (MF), and cellular components (CC)4.     
In addition to the standard difficulties in this type of annotation project, our effort is particularly challenging due to 
our annotating full-text articles and using the full term sets of OBOs. Each of the terminologies we have used has its 
own idiosyncrasies and ambiguities that present further challenges to consistent, high-quality annotation and thus to 
text mining of these articles.  In this paper we present and discuss the most salient of these issues that we have 
encountered in using the GO and addressed in our annotation guidelines and training.  The utility of these guidelines 
can be seen in the high interannotator-agreement (IAA) statistics that we continually monitor. 
Methods 
Manual annotation is performed in an annotation tool developed within our lab called Knowtator5, which is 
implemented as a plugin to Protege-Frames6.  In an effort to reduce the annotators' workloads, the articles were 
preprocessed by automatically tagging them with terms from the relevant ontology; the annotators then check these 
annotations, making any needed deletions or corrections, and mark up anything else that was missed by the 
preprocessing.  All of the annotators' work is further reviewed by the project lead (MB), with subsequent corrections 
being made.  All tagging is saved as standoff annotation.  IAA was calculated by comparing one annotator's set of 
annotations with the set of annotations created as a result of the project lead's review of the set, and Knowtator was 
used to calculate IAA statistics.  Though the GO is continually evolving and growing, we are using a single static 
version (dated November 20, 2007, when this project was initiated) that contains 14,306 biological processes, 7,984 
molecular functions, and 2,047 cellular components. 
Guidelines for Applying the GO toward NLP Annotation 
Given that we are using an ontology of more than 24,000 terms to annotate biomedical journal articles and that we 
strive for high IAA statistics, clear, well-conceived annotation guidelines are critical.  Here we present the higher-
level issues we have encountered and how we have addressed them in our guidelines.  (We also have lower-level, 
linguistics-based guidelines, but this is outside the scope of this paper.) 
 1. Rules for General Biological Processes 
We have found that general words indicating biological processes are particularly difficult to consistently annotate.  
For example: 
(1) Bicarbonate formation is important for aqueous humor secretion from the ciliary processes and carbonic 
anhydrase (CA) facilitates this secretion. [PMID:11532192] 
(2) Cells lacking BRCA1/2 fail to form damage-induced subnuclear RAD51 foci with normal efficiency, suggesting 
that these proteins are required for the formation of recombinase complexes at the sites of DNA damage. 
[PMID:11597317] 
In (1), “formation” is closest to the biological-process term biosynthetic process (which encompasses the 
building up of more complex molecules from simpler ones), while in (2), “formation” is closest to the term 
cellular component assembly, which includes assembly of protein complexes, as is the case here.  Rules 
have helped greatly in the annotation of such general process words.  For example, pertaining to the above 
examples, if lexical variants of “form”, “create”, “assemble”, etc. are applied to molecules, it is likely a biosynthetic 
process; if it is applied to cellular components, it is likely a cellular-component assembly.  Annotating words 
denoting formation of cells and higher-level anatomical structures consistently is still difficult, as the GO cell and 
anatomical-structure development terms are arranged in a complicated (and some would say unintuitive) way.  We 
plan on submitting our suggestions to the GO curation team toward making this part of the ontology clearer. 
2. Molecular Functions vs. Biological Processes 
The GO MF subontology is in a somewhat ambiguous state.  The overwhelming majority of the MF terms are 
defined as molecular-level processes.  (For example, the definition of binding is the “selective, often 
stoichiometric, interaction of a molecule with one or more specific sites on another molecule”.)  Using the 
terminology of the Basic Formal Ontology (BFO), an upper-level ontology that is being used by members of the 
OBO Consortium toward evolution of the OBOs7, a molecular function in this view is an occurrent, i.e., a process, at 
the molecular level.    However, there are those within the OBO Consortium who assert that a GO molecular-
function term denotes not a process but a proper function, which is a dependent continuant, i.e., an abstract entity 
that depends on the existence of another entity—essentially, the potential or functionality inherent in an entity to 
have a process realized3.  It appears that the MF subontology will eventually evolve to this latter conceptualization. 
This is relevant to our annotation work because this dichotomy between a process and the functionality to effect a 
process will often be expressed differently in natural-language text and thus should be annotated differently.  
(However, passages are often ambiguous with regard to process or function.)  We have taken the view that 
molecular functions are processes, partly because this is how they are mostly currently defined and partly because 
mentions of processes are more common and more straightforwardly indicated in natural language than are functions 
to effect processes and thus more easily annotated.   
A conflated issue is the fact that there are corresponding terms in the BP and MF subontologies that are extremely 
difficult to differentiate given a textual mention, even using their defintiions, e.g., BP signal transduction and MF 
signal transducer activity, BP regulation of transcription and MF transcription regulator activity, BP caspase 
activation and MF caspase activator activity, as well as many corresponding BP transport and MF transporter activity 
terms.  We have mostly dealt with this thus far by using most of the MF terms only to annotate text matching the 
term itself or an exact synonym (e.g., kinase activity), an acceptably close synonym (e.g., kinase functionality), or 
the corresponding continuant (e.g., kinase, as discussed later in the paper).  This is a suboptimal solution, but using 
the MF terms in this restricted way has allowed us to maintain our high levels of interannotator agreement. 
A merging of the current MF subontology into the BP subontology to create one ontology of occurrents, from 
molecular-level to organism-level, would go a long way in ameliorating these two interrelated issues.  We realize 
that this may seem radical, but it has been considered before, e.g., at the 2008 NCBO Relation Ontology Expert 
Meeting8.  We assert that this should involve merging the corresponding BP & MF term pairs such as those 
aforementioned.  While the BP ontology would be an ontology of biological occurrents, the MF ontology could be 
redefined as an ontology of biological functions.  An ontology of functions could likely be managed 
semiautomatically, as it would mostly mirror the relevant portions  of the process ontology. 
 3. Noncanonical, Pathological, and Ex Vivo Entities and Processes 
The GO is charged with representing canonical biological processes, molecular functions, and cellular components, 
and so we attempted at first to limit annotation to such canonical entities and processes.  However, this turns out to 
be a deceptively difficult task.  Sometimes the noncanonicality or pathology is explicit, as in: 
(3) There were enlarged extracellular spaces between cells in the equatorial/bow region in 5 wk old alphaA/BKO 
lenses. [PMID:12546709] 
In (3), it is obvious that the extracellular spaces are noncanonical in that they are larger than normal.  But many 
times the noncanonicality or pathology can only be inferred from a very careful reading and comprehension of the 
article, and many other times it is not at all clear.  This is especially due to the fact that most biological articles 
involve experiments with organisms or components of organisms in which they are subjected to all sorts of 
procedures, substances, and environments they would not normally encounter.  Our solution is to annotate all 
mentions of GO entities and processes, even those that are explicitly noncanonical or pathological (so long as all of 
the other rules are followed, of course).  Thus, in (3), “extracellular spaces” is annotated with the GO CC term 
extracellular space even though they are noncanonical in terms of their sizes. 
A related issue is, given that the GO is in the domain of naturally occurring in vivo processes nd cellular entities, 
whether or not their ex vivo counterparts should be annotated.  Analogously, to maximize our IAA, we decided to 
annotate all such ex vivo entities and processes; thus, a binding is a binding whether it takes place in an organism or 
in a beaker. 
Smith et al. have written of noncanonical anatomical parts, which, in their representation with the Ontology of 
Biomedical Reality, are siblings of canonical anatomical parts; both of these are subsumed by a superclass of 
anatomical structures9.  We analogously are viewing the entities and processes of the GO as these more general 
concepts that encompass both canonical and noncanonical instances. 
4. Verb Nominalizations as Occurrents 
Verb nominalizations can refer to either occurrents or continuants; Simon and Smith have written of such duality of 
certain biomedical terms (e.g., dilation, dislocation) and how they address it in their LinKBase system10.  As an 
example from our corpus: 
(4) The vesicle formation goes along with several other changes in the red blood cell like cytoskeleton 
rearrangements and changes in the phospholipid orientation in the cellular membrane. [PMID:12925238] 
In (4), “formation” clearly refers to a process, while “orientation” is a dependent continuant in that it is an attribute 
of the cellular membrane.  We instruct our annotators to not annotate relevant mentions of such words if they clearly 
denote continuants since GO biological processes are occurrents.  However, it is sometimes ambiguous whether 
such a relevant mention refers to either the occurrent or to the dependent continuant, e.g., “distribution” in: 
(5) The differentiation and distribution of specific mature neurons was examined in our previous study at adult 
stages with the expression of striatal markers such as preproenkephalin and Gad65/67. [PMID:15882092] 
In such a case where one of the possible readings denotes an occurrent, we instruct the annotator to mark up the 
mention.  If we had an ontology of the corresponding dependent continuants, we would also mark up such a mention 
with the dependent continuant term, as we encourage multiple annotation to capture the ambiguity of the expression. 
5. Continuants with Molecular Functions 
Mentions of continuants that have functions that can be realized in processes are often more frequent than the 
processes themselves; this is especially true for the molecular-function terms.  For example, mentions of 
recombinases are more frequent than mentions of the MF term recombinase activity.  We wished to capture these 
lexically analogous mentions, so each such mention is annotated with the corresponding term and also with the class 
continuant, the general term denoting an entity in the BFO.  Thus, each such mention is doubly annotated as a 
process and as an entity.  This is actually not semantically correct, as something cannot be both a continuant and an 
occurrent according to the BFO since these are disjoint classes in the BFO.  It would be better to annotate each such 
mention once, as a continuant that has the corresponding function, i.e., by annotating as a continuant and then 
adding a restriction to it, but Knowtator is not currently capable of this type of representation.  Nevertheless, our 
 methodology enables us to capture all information that can then be easily transformed into a more semantically 
correct representation in our annotation repository. 
Results 
At this stage of our annotation of our 97-article corpus, we have created 8,279 annotations of cellular components 
(which is completed) and 18,996 annotations of molecular functions and biological processes in 44 articles (which is 
ongoing).  (One annotator marked up articles with GO CC terms and another is annotating with GO BP and MF 
terms.) 
To demonstrate the utility of our guidelines, we present the IAAs (calculated approximately weekly) for our two GO 
annotation passes in Figure 1.  The annotation of the cellular components quickly rose to approximately 90% or 
higher, while the annotation of the biological processes and molecular functions started very low (9.7%) but has 
significantly risen since, with the last few data points at approximately 80%.  There are large oscillations in the 
graph that are partly due to the fact that this annotator is typically able to annotate only one or two articles per 
period.  A given article often has many mentions of a relatively small set of GO terms, and the IAA statistics are 
subject to such variation if the two annotators consistently annotate these numerous mentions of this relatively small 
set of GO terms differently. 
Figure 1.  IAA statistics for the GO CC and BP/MF annotation projects over time.  Each time period is 
approximately one week.  
Conclusions 
We have encountered issues in the course of our project to annotate biomedical journal articles with the whole of the 
GO, and we have attempted to address them with the guidelines presented in this article.  These guidelines have in 
part allowed us to achieve high IAA statistics using the ontology as a very large annotation schema.  We assert that 
these issues will also be troublesome for attempts at programmatic annotation and text mining of biomedical journal 
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 articles, which many see as necessary in the future.  We have presented several suggestions to the GO that we 
believe could ameliorate these issues. 
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